Synaptic dysfunction represents a critical pathological hallmark in Progressive Supranuclear Palsy (PSP), occurring early in disease progression and contributing to the characteristic motor and cognitive deficits. Unlike Alzheimer's disease where synaptic loss correlates strongly with cognitive decline, PSP demonstrates distinct synaptic pathology patterns that reflect the selective vulnerability of specific neuronal populations and the unique 4R-tau pathology.
In PSP, presynaptic terminals exhibit significant structural and biochemical alterations. Studies demonstrate marked reductions in synaptophysin immunoreactivity in affected brain regions, particularly in the basal ganglia, brainstem, and frontal cortex [1]. The loss of presynaptic markers correlates with the distribution of tau pathology, suggesting that tau aggregation directly impairs synaptic function.
Clathrin-coated vesicle proteins and synaptic vesicle components including synaptotagmin, SV2, and Rab3a show reduced expression in PSP post-mortem tissue [2]. These alterations disrupt neurotransmitter release machinery, leading to impaired synaptic transmission even before significant neuronal loss occurs.
Synaptic dysfunction represents a critical pathological hallmark in Progressive Supranuclear Palsy (PSP), occurring early in disease progression and contributing to the characteristic motor and cognitive deficits. Unlike Alzheimer's disease where synaptic loss correlates strongly with cognitive decline, PSP demonstrates distinct synaptic pathology patterns that reflect the selective vulnerability of specific neuronal populations and the unique 4R-tau pathology.
In PSP, presynaptic terminals exhibit significant structural and biochemical alterations. Studies demonstrate marked reductions in synaptophysin immunoreactivity in affected brain regions, particularly in the basal ganglia, brainstem, and frontal cortex [1]. The loss of presynaptic markers correlates with the distribution of tau pathology, suggesting that tau aggregation directly impairs synaptic function.
Clathrin-coated vesicle proteins and synaptic vesicle components including synaptotagmin, SV2, and Rab3a show reduced expression in PSP post-mortem tissue [2]. These alterations disrupt neurotransmitter release machinery, leading to impaired synaptic transmission even before significant neuronal loss occurs.
Distinct from other tauopathies, PSP demonstrates unique patterns of synaptic tau accumulation. Electron microscopy studies reveal tau filaments within presynaptic terminals, particularly in areas of high synaptic density [3]. The 4R-tau isoform predominates in these synaptic deposits, potentially reflecting differential splicing patterns in vulnerable neurons.
Small oligomeric tau species accumulate at synapses in PSP, representing potentially toxic intermediates that disrupt normal synaptic function before forming larger fibrillary aggregates [4]. These oligomers may spread between neurons via synaptic connectivity, contributing to the progressive spread of pathology.
Beyond tau itself, PSP synapses demonstrate aggregation of multiple synaptic proteins. Synapsin I, which anchors synaptic vesicles to the cytoskeleton, shows altered distribution and reduced phosphorylation in PSP brain tissue [5]. This affects vesicle mobilization and neurotransmitter release kinetics.
Shank proteins, which organize the postsynaptic density, demonstrate tau-mediated sequestration in PSP. The Shank family (Shank1, 2, 3) normally scaffold glutamate receptors and actin at postsynaptic densities; their aggregation disrupts synaptic architecture and receptor trafficking [6].
Synaptic dysfunction in PSP involves impaired calcium homeostasis. Voltage-gated calcium channel subunits show altered expression, particularly N-type channels (Cav2.2) which regulate neurotransmitter release at presynaptic terminals [7]. Reduced calcium influx impairs vesicle fusion and release probability.
Postsynaptic calcium handling also differs from other tauopathies. NMDA receptor subunit composition shifts toward greater GluN2B expression in PSP, potentially increasing excitotoxicity vulnerability while altering synaptic plasticity mechanisms [8].
The basal ganglia demonstrate profound synaptic alterations in PSP, contributing to the characteristic movement disorders. Synaptic loss in the globus pallidus internus (GPi) and substantia nigra pars reticulata (SNr) disrupts the normal inhibitory output that coordinates movement [9].
Dopaminergic synapses in the striatum show particular vulnerability. Tyrosine hydroxylase-positive terminals demonstrate reduced density in PSP, correlating with motor impairment severity [10]. This contrasts with Parkinson's disease where dopaminergic terminal loss precedes synaptic protein changes.
Brainstem nuclei essential for ocular motility and postural control exhibit synaptic alterations disproportionate to neuronal loss. The superior colliculus, which integrates visual and motor signals for eye movements, shows marked synaptic pathology including reduced vesicular glutamate transporter (vGluT) expression [11].
The pedunculopontine nucleus (PPN), critical for arousal and gait initiation, demonstrates synaptic alterations affecting cholinergic transmission. Loss of cholinergic synapses in the PPN contributes to the gait freezing and postural instability characteristic of PSP [12].
While PSP is primarily considered a subcortical disorder, cortical synapses also demonstrate pathology, particularly in frontal regions. Synaptic density reductions in the prefrontal cortex correlate with executive dysfunction and cognitive impairment [13].
Layer-specific cortical synaptic alterations exist, with layer III pyramidal neuron synapses showing particular vulnerability. This pattern differs from Alzheimer's disease which demonstrates more uniform cortical synaptic loss.
Excitatory synaptic transmission via glutamate receptors shows significant impairment in PSP. AMPA receptor subunit composition shifts toward faster kinetics, potentially compensating for reduced presynaptic release [14]. NMDA receptor function remains relatively preserved compared to AD.
Metabotropic glutamate receptors (mGluR) demonstrate altered signaling. Group I mGluRs (mGluR1/5) show reduced coupling to downstream signaling cascades, affecting synaptic plasticity and calcium regulation [15].
Inhibitory GABAergic synapses demonstrate region-specific alterations. Parvalbumin-positive interneurons, which provide critical feedforward inhibition, show reduced synaptic contacts in PSP cortex [16]. This contributes to cortical disinhibition and the release of pathological tau aggregation.
GABAB receptor-mediated presynaptic inhibition remains relatively intact, offering potential therapeutic targeting for modulating excessive cortical excitability [17].
Cholinergic synaptic terminals in the basal forebrain and brainstem demonstrate reduced choline acetyltransferase activity in PSP [18]. This affects both cortical modulation and brainstem reflex circuits.
The pedunculopontine cholinergic synapses show specific vulnerability, contributing to oculomotor and gait dysfunction. Acetylcholinesterase activity remains relatively preserved, suggesting postsynaptic rather than presynaptic cholinergic pathology.
Synaptic alterations in motor-related circuits correlate with specific symptom profiles. Pallidal synaptic loss correlates with bradykinesia severity, while cerebellar input synaptic changes relate to gait ataxia [19].
Early synaptic changes may precede clinical symptoms, suggesting potential for synaptic biomarkers in presymptomatic detection.
Synaptic loss in prefrontal circuits underlies executive dysfunction. The pattern differs from AD, with relative preservation of hippocampal synapses explaining minimal episodic memory impairment in PSP [20].
Synaptic proteins in cerebrospinal fluid show promise as PSP biomarkers. Neurogranin, a dendritic spine protein, demonstrates elevated CSF levels in PSP reflecting synaptic degeneration [21]. Combined with tau measures, synaptic biomarkers may improve diagnostic accuracy.
Small molecules targeting synaptic calcium handling show promise. L-type calcium channel blockers that selectively modulate presynaptic calcium entry may protect synaptic function without affecting cardiac function [22].
Active immunization approaches targeting tau oligomers may reduce synaptic tau burden. Anti-tau antibody treatments in development show potential for entering synapses and clearing pathological tau [23].
Dopaminergic agents provide symptomatic benefit by enhancing remaining synaptic function. Amantadine and other NMDA antagonists may restore synaptic plasticity in basal ganglia circuits [24].
Transcranial magnetic stimulation studies reveal cortical synaptic dysfunction in PSP. Reduced short-interval intracortical inhibition (SICI) indicates GABAergic synaptic circuit impairment [25]. Motor-evoked potential studies demonstrate abnormal synaptic plasticity.
PET tracers targeting synaptic vesicle protein 2A (SV2A) show promise for in vivo synaptic density measurement [26]. These tools may allow longitudinal monitoring of synaptic loss in clinical trials.